<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01616537</url>
  </required_header>
  <id_info>
    <org_study_id>2011-A01063-38</org_study_id>
    <nct_id>NCT01616537</nct_id>
  </id_info>
  <brief_title>Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter</brief_title>
  <acronym>QASICC-EVA</acronym>
  <official_title>Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter: Confirmatory Validation of QASICC Questionnaire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background Patient satisfaction with or acceptance of care assessment is increasingly taken&#xD;
      into account in oncology. Most cancer and other critically-ill patients require a&#xD;
      totally-implanted Central Venous Catheter (CVC) for their treatment consisting of a reservoir&#xD;
      connected to a central venous catheter, which may or may not be valved. It is impossible to&#xD;
      estimate the number of CVC used in oncology. However, some authors claim that, in 2005, over&#xD;
      7 million CVCs were placed in the United States in both chronic and acute care. Although many&#xD;
      patients fitted with a CVC are able to undertake activities which are hindered with other&#xD;
      external vascular access devices, they are often physically or psychologically anxious about&#xD;
      their device. To our knowledge, no validated questionnaire measuring patient acceptance of&#xD;
      and satisfaction with their CVC has been reported in the literature. Based on these&#xD;
      observations, the aim of our study was to develop and to validate a French-language&#xD;
      questionnaire dubbed QASICC (Questionnaire for Acceptance of and Satisfaction with Implanted&#xD;
      Central Venous Catheter) assessing patient satisfaction with and acceptance of their CVC.&#xD;
      QASICC is designed as a multi-dimensional, self-administered questionnaire comprising&#xD;
      approximately 30 items related to the use, appearance and pros and cons of the device as well&#xD;
      as quality of life as perceived by patients using one for treatment.&#xD;
&#xD;
      Objective The purpose of the study is to validate a French-language self-administered&#xD;
      questionnaire (QASICC) designed to evaluate patients' satisfaction and acceptance concerning&#xD;
      their totally-implanted central venous catheter: confirmatory validation of questionnaire&#xD;
      psychometric properties.&#xD;
&#xD;
      Study Design This is a prospective, multicenter, open study.&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      Questionnaire's 27 items tested on 990 patients to confirm QASICC internal structure:&#xD;
&#xD;
        -  Items quality&#xD;
&#xD;
        -  Dimensional structure&#xD;
&#xD;
        -  Dimensional consistence&#xD;
&#xD;
        -  Measure accuracy&#xD;
&#xD;
        -  Measure reliability&#xD;
&#xD;
        -  Sensitivity to change&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      QASICC Questionnaire The QASICC questionnaire included 27 questions (Q) assessing seven&#xD;
      dimensions: pain during placement or use (Q1, Q2), contribution to the comfort of the&#xD;
      treatment (Q3, Q4, Q7, Q10, Q12), esthetics and privacy (Q5, Q6, Q8, Q11, Q17, Q19), the&#xD;
      impact on professional activities, social and sports (Q9, Q13, Q14, Q18, Q20), the impact on&#xD;
      daily activities (Q15, Q16, Q21, Q22 ), local discomfort (Q23, Q24, Q25, Q26) and overall&#xD;
      satisfaction (Q27). The device-related answers were of two types: Likert or visual analogue&#xD;
      scale. Four types of Likert response were available: &quot;no&quot;, &quot;low,&quot; &quot;moderate,&quot;&#xD;
      &quot;significant,&quot;/&quot;never,&quot; &quot;sometimes,&quot; &quot;often,&quot; &quot;always &quot;/&quot; very easy &quot;,&quot; easy &quot;,&quot; difficult&#xD;
      &quot;,&quot; very difficult &quot;/&quot; not at all &quot;,&quot; somewhat &quot;,&quot; a lot &quot;,&quot; extremely &quot;. These questions are&#xD;
      scored 0, 33, 67, 100, respectively, when the scores are correlated with symptoms, or 100,&#xD;
      67, 33, 0 when the scores are inversely correlated with symptoms. Visual analog scales (VAS)&#xD;
      have a length of 100 mm. The score represents the number of mm measured on the scale. A mean&#xD;
      score of acceptance and satisfaction can be calculated on a scale of 0 to 100 for all seven&#xD;
      dimensions using the following formula: {(100-score DO) + CO + score (score ES-100) + (100-PR&#xD;
      score) + (100-ES score) + (score 100-IN) + SA score} / 7. The higher the overall score, the&#xD;
      greater the acceptance and satisfaction&#xD;
&#xD;
      The questionnaire is administered to the patient 30 days (+/-7 days) after CVC implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QASICC questionnaire's 27 items tested on 990 patients to confirm the internal structure</measure>
    <time_frame>30 days (+/- 7 days) after CVC implantation</time_frame>
    <description>Items quality&#xD;
Dimensional structure&#xD;
Dimensional consistence&#xD;
Measure accuracy&#xD;
Measure reliability&#xD;
Sensitivity to change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire's 27 items tested on 990 patients to confirm QASICC external structure: convergent-divergent validity compared to EORTC-QLQC30 questionnaire.</measure>
    <time_frame>30 days (+/-7 days) after CVC implantation</time_frame>
    <description>convergent-divergent validity of the QASICC questionnaire compared to EORTC-QLQC30 questionnaire</description>
  </secondary_outcome>
  <enrollment type="Actual">990</enrollment>
  <condition>Malignant Mast Cell Tumors</condition>
  <condition>Solid Organ Sites</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QUALITY OF LIFE QUESTIONNAIRE</intervention_name>
    <description>QASICC AND EORTC QLQ-C30 ADMINISTRATION 30 DAYS AFTER CVC IMPLANTATION</description>
    <other_name>QASICC</other_name>
    <other_name>EORTC QLQ-C30</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
          -  Patient who benefited or will benefit from the implantation of a CVC&#xD;
&#xD;
          -  Solid tumor or hematologic malignancy&#xD;
&#xD;
          -  WHO Performance Status 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any severe psychopathological disorder preventing completion of the questionnaire or&#xD;
             invalidating questionnaire's measures&#xD;
&#xD;
          -  Severe depressive state&#xD;
&#xD;
          -  Non malignant pathology&#xD;
&#xD;
          -  Inability to respond to questionnaires&#xD;
&#xD;
          -  Patient not speaking fluent French&#xD;
&#xD;
          -  Patient unable to consent&#xD;
&#xD;
          -  Patient under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PIERRE YVES MARCY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin - Ico</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>June 7, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <last_update_submitted>November 13, 2015</last_update_submitted>
  <last_update_submitted_qc>November 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumors</keyword>
  <keyword>hematological malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mast-Cell Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

